guest ::
| Home > Publications Database > Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas. > print |
| Home > Publications Database > Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas. > print |
| 001 | 281528 | ||
| 005 | 20251102002100.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.125.270115 |2 doi |
| 024 | 7 | _ | |a pmid:40935608 |2 pmid |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 024 | 7 | _ | |a altmetric:181362085 |2 altmetric |
| 037 | _ | _ | |a DZNE-2025-01146 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ebner, Ricarda |b 0 |
| 245 | _ | _ | |a Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas. |
| 260 | _ | _ | |a New York, NY |c 2025 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761740421_30624 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Methods: We conducted a retrospective analysis of 8,077 SSTR imaging studies recorded in our institutional database between 2006 and 2021. In total, 223 SSTR PET/CT scans were performed for suspected meningioma, and 240 lesions were matched with histopathology results within 4 mo. Reports from SSTR PET/CT scans and histopathology were retrospectively reviewed to assess the presence of intracranial meningiomas. The positive and negative predictive values, sensitivity, specificity, and overall diagnostic accuracy of SSTR PET/CT were calculated. The SUVmax, SUVmean, and SUVpeak were determined for each lesion. Results: In 222 (92.5%) of 240 lesions, meningioma was accurately identified by SSTR PET/CT and confirmed by histopathology. In 7 cases (2.9%), SSTR PET/CT suspected meningioma was not confirmed by histopathology (false-positive). Furthermore, in 11 cases (5%), meningioma was neither suspected by SSTR PET/CT nor confirmed by histopathology (true-negative result). There were no false-negative findings in our cohort. SSTR PET/CT demonstrated a sensitivity of 100% (95% CI, 98.4%-100%) and a specificity of 61.1% (95% CI, 35.8%-82.7%) in detecting meningiomas. Positive predictive value was 96.9% (95% CI, 93.8%-98.8%), and negative predictive value was 100% (95% CI, 71.5%-100%). The overall diagnostic accuracy was 97.1%. The receiver-operating-characteristic analysis for SUVmax in predicting histopathology results showed an area under the curve of 94%, indicating an excellent ability of SUVmax to distinguish between positive and negative histopathologic findings. Conclusion: SSTR PET/CT is a precise imaging modality for detecting intracranial meningiomas, as demonstrated by its high sensitivity. However, in 2.9% of cases, despite a positive PET/CT result, histopathology did not confirm the presence of a meningioma. Integration of MRI, histopathology, and SSTR PET/CT supports informed treatment decisions. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a PET |2 Other |
| 650 | _ | 7 | |a histopathology |2 Other |
| 650 | _ | 7 | |a magnetic resonance imaging |2 Other |
| 650 | _ | 7 | |a meningioma |2 Other |
| 650 | _ | 7 | |a somatostatin receptor |2 Other |
| 650 | _ | 7 | |a Receptors, Somatostatin |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Meningioma: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Meningioma: pathology |2 MeSH |
| 650 | _ | 2 | |a Meningioma: metabolism |2 MeSH |
| 650 | _ | 2 | |a Receptors, Somatostatin: metabolism |2 MeSH |
| 650 | _ | 2 | |a Positron Emission Tomography Computed Tomography |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Meningeal Neoplasms: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Meningeal Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Meningeal Neoplasms: metabolism |2 MeSH |
| 650 | _ | 2 | |a Sensitivity and Specificity |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 700 | 1 | _ | |a Braach, Jana |b 1 |
| 700 | 1 | _ | |a Rübenthaler, Johannes |b 2 |
| 700 | 1 | _ | |a Cyran, Clemens C |b 3 |
| 700 | 1 | _ | |a Sheikh, Gabriel T |b 4 |
| 700 | 1 | _ | |a Brendel, Matthias |0 P:(DE-2719)9001539 |b 5 |u dzne |
| 700 | 1 | _ | |a Albert, Nathalie L |b 6 |
| 700 | 1 | _ | |a Tiling, Reinhold |b 7 |
| 700 | 1 | _ | |a Greve, Tobias |b 8 |
| 700 | 1 | _ | |a Hinterberger, Anna |b 9 |
| 700 | 1 | _ | |a Fabritius, Matthias P |b 10 |
| 700 | 1 | _ | |a Fink, Nicola |b 11 |
| 700 | 1 | _ | |a Ricke, Jens |b 12 |
| 700 | 1 | _ | |a Werner, Rudolf A |b 13 |
| 700 | 1 | _ | |a Grawe, Freba |b 14 |
| 773 | _ | _ | |a 10.2967/jnumed.125.270115 |g Vol. 66, no. 10, p. 1561 - 1567 |0 PERI:(DE-600)2040222-3 |n 10 |p 1561 - 1567 |t Journal of nuclear medicine |v 66 |y 2025 |x 0097-9058 |
| 909 | C | O | |o oai:pub.dzne.de:281528 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)9001539 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-01 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-01 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 920 | 1 | _ | |0 I:(DE-2719)1110007 |k AG Haass |l Molecular Neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1110007 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|